Methods and systems for treating cell proliferation disorders using plasmonics enhanced photospectral therapy (PEPST) and exciton-plasmon enhanced phototherapy (EPEP)

Patent metadata

Field	Value
Publication number	US-9283275-B2
Application number	US-201414573511-A
Country	US
Kind code	B2
Filing date	Dec 17, 2014
Priority date	Aug 6, 2007
Publication date	Mar 15, 2016
Grant date	Mar 15, 2016

Abstract

The use of plasmonics enhanced photospectral therapy (PEPST) and exiton-plasmon enhanced phototherapy (EPEP) in the treatment of various cell proliferation disorders, and the PEPST and EPEP agents and probes used therein.

First claim

The invention claimed is:

1. A method for treating a cell proliferation disorder in a subject, comprising:
(1) administering to the subject an effective amount of a pharmaceutical composition comprising:
at least one activatable pharmaceutical agent capable of activation and of causing non-lytic cell death upon activation, wherein the at least one activatable pharmaceutical agent is a psoralen or a coumarin;
at least one plasmonics-active agent capable of enhancing or modifying energy, wherein the at least one plasmonics-active agent is at least one member selected from the group consisting of gold, silver, platinum, palladium, nickel, ruthenium, rhenium, copper, and cobalt;
at least one energy modulation agent capable of activating the at least one activatable pharmaceutical agent when energized, wherein the at least one energy modulation agent is at least one member selected from the group consisting of CdS, CsCl, ZnS, Er 3+ doped BaTiO 3 , Yb 3+ doped CsMnCl 3 , CdTe, CdSe, ZnO, CdS, Y 2 O 3 , MgS, CaS, SrS, BaS, BaF 2 , BaFBr, BaTiO 3 , ZnS:Mn,Er; ZnSe:Mn,Er; MgS:Mn,Er; CaS:Mn,Er; ZnS:Mn,Yb; ZnSe:Mn,Yb; MgS:Mn,Yb; CaS:Mn,Yb; ZnS:Tb 3+ , Er 3+ ; ZnS:Tb 3+ ; Y 2 O 3 :Tb 3+ ; Y 2 O 3 :Tb 3+ , Er3 + ; ZnS:Mn 2+ ; and ZnS:Mn,Er 3+ ; and
a pharmaceutically acceptable carrier,
wherein the pharmaceutical composition is in a form of a plasmonics enhanced photospectral therapy (PEPST) probe comprising (a) the at least one plasmonics active agent as a plasmonics active metal nanoparticle, (b) the at least one activatable pharmaceutical agent, and (c) the at least one energy modulation agent, and has a configuration selected from the following:
the at least one activatable pharmaceutical agent bound to the at least one energy modulation agent, which is bound to the at least one plasmonics active metal nanoparticle;
the at least one plasmonics active metal nanoparticle having a nanocap formed of the at least one energy modulation agent, wherein the nanocap has attached thereto molecules of the at least one activatable pharmaceutical agent;
nanoparticles of the at least one energy modulation agent having on a surface thereof a mixture of the at least one plasmonics active metal nanoparticles and the at least one activatable pharmaceutical agent;
nanoparticles of the at least one energy modulation agent having a nanocap formed of the at least one plasmonics active metal nanoparticle, wherein the nanoparticles of the at least one energy modulation agent also have on a surface thereof molecules of the at least one activatable pharmaceutical agent;
a core formed from the at least one plasmonics active metal nanoparticle having a nanoshell formed of the at least one energy modulation agent, wherein the nanoshell has on a surface thereof molecules of the at least one activatable pharmaceutical agent; or
at least one nanoparticle of the at least one plasmonics active metal nanoparticle attached to at least one nanoparticle of the at least one energy modulation agent, wherein the at least one nanoparticle of the at least one energy modulation agent has the at least one activatable pharmaceutical agent attached thereto by a detachable biochemical bond, and

(3) applying an initiation energy from an initiation energy source to the subject,
wherein the plasmonics-active agent enhances or modifies the applied initiation energy, such that the enhanced or modified initiation energy activates the activatable pharmaceutical agent in situ,
thus causing the predetermined cellular change to occur, wherein said predetermined cellular change treats the cell proliferation related disorder.

2. The method according to claim 1 , wherein the at least one activatable pharmaceutical agent is 8-methoxypsoralen (8-MOP) or 4′-aminomethyl-4,5′,8-trimethylpsoralen (AMT).

3. The method of claim 1 , wherein the non-lytic cell death is apoptosis in a target cell.

4. The method of claim 1 , wherein said at least one energy modulation agent is a single energy modulation agent, and is coupled to said at least one activatable pharmaceutical agent.

5. The method of claim 1 , wherein the PEPST probe has a configuration wherein the core is formed from the at least one plasmonics active metal nanoparticle having the nanoshell formed of the at least one energy modulation agent, wherein the nanoshell has molecules of the at least one activatable pharmaceutical agent bound to the surface thereof.

6. The method of claim 5 , wherein the at least one plasmonics active metal nanoparticle is a gold nanoparticle and the at least one energy modulation agent is Y 2 O 3 .

7. The method of claim 1 , wherein the at least one plasmonics active agent is gold, the at least one energy modulation agent is Y 2 O 3 , and the at least one pharmaceutical agent is 8-methoxypsoralen (8-MOP).

8. A system for producing an auto-vaccine in a subject, comprising:
a pharmaceutical composition comprising:
at least one activatable pharmaceutical agent capable of activation and of causing non-lytic cell death upon activation, wherein the at least one activatable pharmaceutical agent is a psoralen or a coumarin;
at least one plasmonics-active agent capable of enhancing or modifying energy, wherein the at least one plasmonics-active agent is at least one member selected from the group consisting of gold, silver, platinum, palladium, nickel, ruthenium, rhenium, copper, and cobalt;
at least one energy modulation agent capable of activating the at least one activatable pharmaceutical agent when energized, wherein the at least one energy modulation agent is at least one member selected from the group consisting of CdS, CsCl, ZnS, Er 3+ doped BaTiO 3 , Yb 3+ doped CsMnCl 3 , CdTe, CdSe, ZnO, CdS, Y 2 O 3 , MgS, CaS, SrS, BaS, BaF 2 , BaFBr, BaTiO 3 , ZnS:Mn,Er; ZnSe:Mn,Er; MgS:Mn,Er; CaS:Mn,Er; ZnS:Mn,Yb; ZnSe:Mn,Yb; MgS:Mn,Yb; CaS:Mn,Yb; ZnS:Tb 3+ , Er 3+ ; ZnS:Tb 3+ ; Y 2 O 3 :Tb 3+ ; Y 2 O 3 :Tb 3+ , Er3 + ; ZnS:Mn 2+ ; and ZnS:Mn,Er 3+ ; and
a pharmaceutically acceptable carrier,
wherein the pharmaceutical composition is in a form of a plasmonics enhanced photospectral therapy (PEPST) probe comprising (a) the at least one plasmonics active agent as a plasmonics active metal nanoparticle, (b) the at least one activatable pharmaceutical agent, and (c) the at least one energy modulation agent, and has a configuration selected from the following:
the at least one activatable pharmaceutical agent bound to the at least one energy modulation agent, which is bound to the at least one plasmonics active metal nanoparticle;
the at least one plasmonics active metal nanoparticle having a nanocap formed of the at least one energy modulation agent, wherein the nanocap has attached thereto molecules of the at least one activatable pharmaceutical agent;
nanoparticles of the at least one energy modulation agent having on a surface thereof a mixture of the at least one plasmonics active metal nanoparticles and the at least one activatable pharmaceutical agent;
nanoparticles of the at least one energy modulation agent having a nanocap formed of the at least one plasmonics active metal nanoparticle, wherein the nanoparticles of the at least one energy modulation agent also have on a surface thereof molecules of the at least one activatable pharmaceutical agent;
a core formed from the at least one plasmonics active metal nanoparticle having a nanoshell formed of the at least one energy modulation agent, wherein the nanoshell has on a surface thereof molecules of the at least one activatable pharmaceutical agent; or
at least one nanoparticle of the at least one plasmonics active metal nanoparticle attached to at least one nanoparticle of the at least one energy modulation agent, wherein the at least one nanoparticle of the at least one energy modu

Assignees

• Univ Duke
• Immunolight Llc
• Immunolight

Inventors

• Vo-Dinh Tuan
• Bourke Jr Frederic A

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61K2039/57

  characterised by the type of response, e.g. Th1, Th2 · CPC title

• A61K41/0061 Primary

  5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA · CPC title